US 11,911,511 · Application 17/201,811 · Granted Feb 27, 2024
US 11,911,511
Anticancer compositions
Estimated expiration
December 3, 2035
9y 66d remaining
Earliest effective filing
Dec 3, 2015
+ 20 years
Dec 3, 2035
PTA +360d
Nov 27, 2036
TD cap (US 10,285,948)
Dec 3, 2035
Final
Dec 3, 2035
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- March 15, 2021
- Earliest effective filing
- December 3, 2015
- Issue date
- February 27, 2024
- PTA
- +360 days
- Base expiry (before PTA)
- December 3, 2035
December 3, 2015 + 20 years = December 3, 2035 + 360 PTA days = November 27, 2036
- Continuation of application 16/357,821, filed Mar 19, 2019, issued as US 11,224,575
- Continuation of application 15/533,229, filed Jun 5, 2017, issued as US 10,285,948
- National stage entry of application PCTUS2015063671, filed Dec 3, 2015
- National stage entry of application PCTUS2015063671, filed Dec 3, 2015
- Continuation of application 15/533,229, filed Jun 5, 2017, issued as US 10,285,948
- National stage entry of application PCTUS2015063671, filed Dec 3, 2015
Terminal disclaimers
TD caps expiration to December 3, 2035 (earliest expiring referenced patent: US 10,285,948)
US 3,693,002
Could not resolve calculation details
US 10,285,948· Application 15/533,229Capping patent
Anticancer compositions
- Filing date
- Jun 5, 2017
- Earliest effective filing
- Dec 3, 2015
- Issue date
- May 14, 2019
- PTA
- 0 days
- Calculated expiration
- Dec 3, 2035
National stage entry of PCTUS2015063671, filed Dec 3, 2015
Dec 3, 2015 + 20y = Dec 3, 2035
US 11,224,575· Application 16/357,821
Anticancer compositions
- Filing date
- Mar 19, 2019
- Earliest effective filing
- Dec 3, 2015
- Issue date
- Jan 18, 2022
- PTA
- 0 days
- Calculated expiration
- Dec 3, 2035
Continuation of 15/533,229, filed Jun 5, 2017, issued as US 10,285,948
National stage entry of PCTUS2015063671, filed Dec 3, 2015
National stage entry of PCTUS2015063671, filed Dec 3, 2015
Dec 3, 2015 + 20y = Dec 3, 2035
US 11,911,511· Application 17/201,811(from application 17/201,811)
Anticancer compositions
- Filing date
- Mar 15, 2021
- Earliest effective filing
- Dec 3, 2015
- Issue date
- Feb 27, 2024
- PTA
- +360 days
- Calculated expiration
- Nov 27, 2036
Continuation of 16/357,821, filed Mar 19, 2019, issued as US 11,224,575
Continuation of 15/533,229, filed Jun 5, 2017, issued as US 10,285,948
National stage entry of PCTUS2015063671, filed Dec 3, 2015
National stage entry of PCTUS2015063671, filed Dec 3, 2015
Continuation of 15/533,229, filed Jun 5, 2017, issued as US 10,285,948
National stage entry of PCTUS2015063671, filed Dec 3, 2015
Dec 3, 2015 + 20y + 360d PTA = Nov 27, 2036
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 17/201,811 · US 11,911,511
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 11,911,511: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US11911511Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.